Huiting Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Huiting Xu has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Chongge You
Laboratory Medicine Center, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China
6 shared publications - Chuanxin Wang
Department of Clinical Laboratory, The Second Hospital of Shandong University, Jinan, China
6 shared publications - Dong Sun
Department of General Surgery, Qilu Hospital of Shandong University, Jinan, P.R. China
6 shared publications - Guanghua Li
Department of Clinical Laboratory, Guangdong Provincial People's Hospital/Guangdong Academy of Medical Sciences, Guangzhou, P.R. China
6 shared publications - Jing Wang
Department of Clinical Laboratory, The Second Hospital of Shandong University, Jinan, P.R. China
6 shared publications - Juan Li
Department of Clinical Laboratory, The Second Hospital of Shandong University, Jinan, China
6 shared publications
Latest Publications
- Open Access
- 1 January 2025
- Published by Wiley in Human Mutation
- Vol. 2025 (1) , 9034896
Exploring the Molecular Functions and Immune Relevance of Macrophage‐Associated Genes in Atherosclerosis
Atherosclerosis is a common and significant cardiovascular condition that frequently goes undiagnosed by conventional diagnostic and treatment techniques until it reaches a more advanced stage. This challenge impedes the capacity to apply early detection and intervention measures. As a result, the creation of innovative and more accurate biomarkers is critically important. The study first recognizes genes associated with macrophages through single‐cell analysis, investigating their functions. Subsequently, various machine learning approaches are utilized to identify significant regulatory genes related to macrophages. In addition, molecular docking studies are performed to evaluate the binding affinity of these crucial markers with therapeutics targeting atherosclerosis. The ImmuCellAI platform is also utilized to assess immune cell scores in atherosclerotic samples, aiding in the examination of connections between vital diagnostic markers and immune cells. Finally, the expression changes of the selected key genes are confirmed using qRT‐PCR and Western blot methods. Through analyses at the single‐cell level and differential assessments, we discovered 58 genes related to macrophages that exhibited differential expression. Functional evaluations indicated a strong correlation between these genes and the immune microenvironment. By conducting cluster analysis, we assessed how different subgroups of patients with atherosclerosis respond to immunotherapy. Utilizing techniques such as XGBoost, random forest, and the GOsemsim algorithm, we pinpointed five crucial diagnostic markers. Studies on molecular docking validated that these important markers could act as potential drug targets for atherosclerosis. Finally, our experimental analysis revealed a significant overexpression of these five diagnostic markers in tissues affected by atherosclerosis. This research introduces novel diagnostic indicators associated with macrophages in atherosclerosis and emphasizes their potential as targets for therapies related to the immune system.
- 1 January 2025
- Published by Wiley in Human Mutation
- Vol. 2025 (1) , 9034896
Open AccessExploring the Molecular Functions and Immune Relevance of Macrophage‐Associated Genes in Atherosclerosis
Atherosclerosis is a common and significant cardiovascular condition that frequently goes undiagnosed by conventional diagnostic and treatment techniques until it reaches a more advanced stage. This challenge impedes the capacity to apply early detection and intervention measures. As a result, the creation of innovative and more accurate biomarkers is critically important. The study first recognizes genes associated with macrophages through single‐cell analysis, investigating their functions. Subsequently, various machine learning approaches are utilized to identify significant regulatory genes related to macrophages. In addition, molecular docking studies are performed to evaluate the binding affinity of these crucial markers with therapeutics targeting atherosclerosis. The ImmuCellAI platform is also utilized to assess immune cell scores in atherosclerotic samples, aiding in the examination of connections between vital diagnostic markers and immune cells. Finally, the expression changes of the selected key genes are confirmed using qRT‐PCR and Western blot methods. Through analyses at the single‐cell level and differential assessments, we discovered 58 genes related to macrophages that exhibited differential expression. Functional evaluations indicated a strong correlation between these genes and the immune microenvironment. By conducting cluster analysis, we assessed how different subgroups of patients with atherosclerosis respond to immunotherapy. Utilizing techniques such as XGBoost, random forest, and the GOsemsim algorithm, we pinpointed five crucial diagnostic markers. Studies on molecular docking validated that these important markers could act as potential drug targets for atherosclerosis. Finally, our experimental analysis revealed a significant overexpression of these five diagnostic markers in tissues affected by atherosclerosis. This research introduces novel diagnostic indicators associated with macrophages in atherosclerosis and emphasizes their potential as targets for therapies related to the immune system.
- Open Access
- 1 November 2023
- Published by American Association for Cancer Research (AACR)
Data from DNA Methylation-Based Testing in Peripheral Blood Mononuclear Cells Enables Accurate and Early Detection of Colorectal Cancer
An effective blood-based method for the diagnosis of colorectal cancer has not yet been developed. Molecular alterations of immune cells occur early in tumorigenesis, providing the theoretical underpinning for early cancer diagnosis based on immune cell profiling. Therefore, we aimed to develop an effective detection method based on peripheral blood mononuclear cells (PBMC) to improve the diagnosis of colorectal cancer. Analysis of the genome-wide methylation landscape of PBMCs from patients with colorectal cancer and healthy controls by microarray, pyrosequencing, and targeted bisulfite sequencing revealed five DNA methylation markers for colorectal cancer diagnosis, especially early-stage colorectal cancer. A single-tube multiple methylation–specific quantitative PCR assay (multi-msqPCR) for simultaneous detection of five methylation markers was established, which allowed quantitative analysis of samples with as little as 0.1% PBMC DNA and had better discriminative performance than single-molecule detection. Then, a colorectal cancer diagnostic model (CDM) based on methylation markers and the multi-msqPCR method was constructed that achieved high accuracy for early-stage colorectal cancer (AUC = 0.91; sensitivity = 81.18%; specificity = 89.39%), which was improved compared with CEA (AUC = 0.79). The CDM also enabled a high degree of discrimination for advanced adenoma cases (AUC = 0.85; sensitivity = 63.04%). Follow-up data also demonstrated that the CDM could identify colorectal cancer potential up to 2 years before currently used diagnostic methods. In conclusion, the approach constructed in this study based on PBMC-derived DNA methylation markers and a multi-msqPCR method is a promising and easily implementable diagnostic method for early-stage colorectal cancer.Significance:Development of a diagnostic model for early colorectal cancer based on epigenetic analysis of PBMCs supports the utility of altered DNA methylation in immune cells for cancer diagnosis.
- 1 November 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from DNA Methylation-Based Testing in Peripheral Blood Mononuclear Cells Enables Accurate and Early Detection of Colorectal Cancer
An effective blood-based method for the diagnosis of colorectal cancer has not yet been developed. Molecular alterations of immune cells occur early in tumorigenesis, providing the theoretical underpinning for early cancer diagnosis based on immune cell profiling. Therefore, we aimed to develop an effective detection method based on peripheral blood mononuclear cells (PBMC) to improve the diagnosis of colorectal cancer. Analysis of the genome-wide methylation landscape of PBMCs from patients with colorectal cancer and healthy controls by microarray, pyrosequencing, and targeted bisulfite sequencing revealed five DNA methylation markers for colorectal cancer diagnosis, especially early-stage colorectal cancer. A single-tube multiple methylation–specific quantitative PCR assay (multi-msqPCR) for simultaneous detection of five methylation markers was established, which allowed quantitative analysis of samples with as little as 0.1% PBMC DNA and had better discriminative performance than single-molecule detection. Then, a colorectal cancer diagnostic model (CDM) based on methylation markers and the multi-msqPCR method was constructed that achieved high accuracy for early-stage colorectal cancer (AUC = 0.91; sensitivity = 81.18%; specificity = 89.39%), which was improved compared with CEA (AUC = 0.79). The CDM also enabled a high degree of discrimination for advanced adenoma cases (AUC = 0.85; sensitivity = 63.04%). Follow-up data also demonstrated that the CDM could identify colorectal cancer potential up to 2 years before currently used diagnostic methods. In conclusion, the approach constructed in this study based on PBMC-derived DNA methylation markers and a multi-msqPCR method is a promising and easily implementable diagnostic method for early-stage colorectal cancer.Significance:Development of a diagnostic model for early colorectal cancer based on epigenetic analysis of PBMCs supports the utility of altered DNA methylation in immune cells for cancer diagnosis.
- Open Access
- 1 November 2023
- Published by American Association for Cancer Research (AACR)
Data from DNA Methylation-Based Testing in Peripheral Blood Mononuclear Cells Enables Accurate and Early Detection of Colorectal Cancer
An effective blood-based method for the diagnosis of colorectal cancer has not yet been developed. Molecular alterations of immune cells occur early in tumorigenesis, providing the theoretical underpinning for early cancer diagnosis based on immune cell profiling. Therefore, we aimed to develop an effective detection method based on peripheral blood mononuclear cells (PBMC) to improve the diagnosis of colorectal cancer. Analysis of the genome-wide methylation landscape of PBMCs from patients with colorectal cancer and healthy controls by microarray, pyrosequencing, and targeted bisulfite sequencing revealed five DNA methylation markers for colorectal cancer diagnosis, especially early-stage colorectal cancer. A single-tube multiple methylation–specific quantitative PCR assay (multi-msqPCR) for simultaneous detection of five methylation markers was established, which allowed quantitative analysis of samples with as little as 0.1% PBMC DNA and had better discriminative performance than single-molecule detection. Then, a colorectal cancer diagnostic model (CDM) based on methylation markers and the multi-msqPCR method was constructed that achieved high accuracy for early-stage colorectal cancer (AUC = 0.91; sensitivity = 81.18%; specificity = 89.39%), which was improved compared with CEA (AUC = 0.79). The CDM also enabled a high degree of discrimination for advanced adenoma cases (AUC = 0.85; sensitivity = 63.04%). Follow-up data also demonstrated that the CDM could identify colorectal cancer potential up to 2 years before currently used diagnostic methods. In conclusion, the approach constructed in this study based on PBMC-derived DNA methylation markers and a multi-msqPCR method is a promising and easily implementable diagnostic method for early-stage colorectal cancer.Significance:Development of a diagnostic model for early colorectal cancer based on epigenetic analysis of PBMCs supports the utility of altered DNA methylation in immune cells for cancer diagnosis.
- 1 November 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from DNA Methylation-Based Testing in Peripheral Blood Mononuclear Cells Enables Accurate and Early Detection of Colorectal Cancer
An effective blood-based method for the diagnosis of colorectal cancer has not yet been developed. Molecular alterations of immune cells occur early in tumorigenesis, providing the theoretical underpinning for early cancer diagnosis based on immune cell profiling. Therefore, we aimed to develop an effective detection method based on peripheral blood mononuclear cells (PBMC) to improve the diagnosis of colorectal cancer. Analysis of the genome-wide methylation landscape of PBMCs from patients with colorectal cancer and healthy controls by microarray, pyrosequencing, and targeted bisulfite sequencing revealed five DNA methylation markers for colorectal cancer diagnosis, especially early-stage colorectal cancer. A single-tube multiple methylation–specific quantitative PCR assay (multi-msqPCR) for simultaneous detection of five methylation markers was established, which allowed quantitative analysis of samples with as little as 0.1% PBMC DNA and had better discriminative performance than single-molecule detection. Then, a colorectal cancer diagnostic model (CDM) based on methylation markers and the multi-msqPCR method was constructed that achieved high accuracy for early-stage colorectal cancer (AUC = 0.91; sensitivity = 81.18%; specificity = 89.39%), which was improved compared with CEA (AUC = 0.79). The CDM also enabled a high degree of discrimination for advanced adenoma cases (AUC = 0.85; sensitivity = 63.04%). Follow-up data also demonstrated that the CDM could identify colorectal cancer potential up to 2 years before currently used diagnostic methods. In conclusion, the approach constructed in this study based on PBMC-derived DNA methylation markers and a multi-msqPCR method is a promising and easily implementable diagnostic method for early-stage colorectal cancer.Significance:Development of a diagnostic model for early colorectal cancer based on epigenetic analysis of PBMCs supports the utility of altered DNA methylation in immune cells for cancer diagnosis.
- Open Access
- 21 August 2023
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 83 (21) , 3636-3649
DNA Methylation-Based Testing in Peripheral Blood Mononuclear Cells Enables Accurate and Early Detection of Colorectal Cancer
An effective blood-based method for the diagnosis of colorectal cancer has not yet been developed. Molecular alterations of immune cells occur early in tumorigenesis, providing the theoretical underpinning for early cancer diagnosis based on immune cell profiling. Therefore, we aimed to develop an effective detection method based on peripheral blood mononuclear cells (PBMC) to improve the diagnosis of colorectal cancer. Analysis of the genome-wide methylation landscape of PBMCs from patients with colorectal cancer and healthy controls by microarray, pyrosequencing, and targeted bisulfite sequencing revealed five DNA methylation markers for colorectal cancer diagnosis, especially early-stage colorectal cancer. A single-tube multiple methylation–specific quantitative PCR assay (multi-msqPCR) for simultaneous detection of five methylation markers was established, which allowed quantitative analysis of samples with as little as 0.1% PBMC DNA and had better discriminative performance than single-molecule detection. Then, a colorectal cancer diagnostic model (CDM) based on methylation markers and the multi-msqPCR method was constructed that achieved high accuracy for early-stage colorectal cancer (AUC = 0.91; sensitivity = 81.18%; specificity = 89.39%), which was improved compared with CEA (AUC = 0.79). The CDM also enabled a high degree of discrimination for advanced adenoma cases (AUC = 0.85; sensitivity = 63.04%). Follow-up data also demonstrated that the CDM could identify colorectal cancer potential up to 2 years before currently used diagnostic methods. In conclusion, the approach constructed in this study based on PBMC-derived DNA methylation markers and a multi-msqPCR method is a promising and easily implementable diagnostic method for early-stage colorectal cancer. Significance: Development of a diagnostic model for early colorectal cancer based on epigenetic analysis of PBMCs supports the utility of altered DNA methylation in immune cells for cancer diagnosis.
- 21 August 2023
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 83 (21) , 3636-3649
Open AccessDNA Methylation-Based Testing in Peripheral Blood Mononuclear Cells Enables Accurate and Early Detection of Colorectal Cancer
An effective blood-based method for the diagnosis of colorectal cancer has not yet been developed. Molecular alterations of immune cells occur early in tumorigenesis, providing the theoretical underpinning for early cancer diagnosis based on immune cell profiling. Therefore, we aimed to develop an effective detection method based on peripheral blood mononuclear cells (PBMC) to improve the diagnosis of colorectal cancer. Analysis of the genome-wide methylation landscape of PBMCs from patients with colorectal cancer and healthy controls by microarray, pyrosequencing, and targeted bisulfite sequencing revealed five DNA methylation markers for colorectal cancer diagnosis, especially early-stage colorectal cancer. A single-tube multiple methylation–specific quantitative PCR assay (multi-msqPCR) for simultaneous detection of five methylation markers was established, which allowed quantitative analysis of samples with as little as 0.1% PBMC DNA and had better discriminative performance than single-molecule detection. Then, a colorectal cancer diagnostic model (CDM) based on methylation markers and the multi-msqPCR method was constructed that achieved high accuracy for early-stage colorectal cancer (AUC = 0.91; sensitivity = 81.18%; specificity = 89.39%), which was improved compared with CEA (AUC = 0.79). The CDM also enabled a high degree of discrimination for advanced adenoma cases (AUC = 0.85; sensitivity = 63.04%). Follow-up data also demonstrated that the CDM could identify colorectal cancer potential up to 2 years before currently used diagnostic methods. In conclusion, the approach constructed in this study based on PBMC-derived DNA methylation markers and a multi-msqPCR method is a promising and easily implementable diagnostic method for early-stage colorectal cancer. Significance: Development of a diagnostic model for early colorectal cancer based on epigenetic analysis of PBMCs supports the utility of altered DNA methylation in immune cells for cancer diagnosis.